cell) and antibody responses.
-- More volunteers had antibody responses to the full dose than to the
1/10th dose vaccine, whereas response rates for T cells were similar
for the 1/10th and full dose.
-- 2nd MVA vaccination positively increased the number of CD8 T cell
responders and antibody responders.
-- Excellent results led to authorization to start two new trials with
GeoVax HIV/AIDS vaccines which began in June 2007.
These human trials, utilizing GeoVax's HIV/AIDS vaccines, are conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded and supported by the National Institutes of Health (NIH), is the largest worldwide clinical trials program devoted to the development and testing of HIV/AIDS vaccines. Preclinical work enabling development of the clinical evaluation of GeoVax's DNA and MVA vaccines was also funded and
supported by the NIH National Institute of Allergy and Infectious Diseases (NIAID).
About GeoVax Labs, Inc. (http://www.geovax.com)
GeoVax Inc. is an Atlanta, Georgia USA biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is protected by 20 issued and filed patent applications.
GeoVax's DNA and Recombinant MVA HIV/AIDS vaccines:
-- Uses DNA for priming the vaccine responses and recombinant MVA to boost
the vaccine response (DNA/MVA vaccine)
-- Protected 22 of 23 (96%) non-human primates for over 3-1/2 years post-
infection with an AIDS causing virus - 5 of 6 non-vaccinated controls
died of AIDS within the 1st year of infection. These trials used a
prototype SIV/HIV vaccine for the HIV vaccine that is being advanced in
-- Are manufac
|SOURCE GeoVax Labs, Inc.|
Copyright©2007 PR Newswire.
All rights reserved